OSLO, Norway--(BUSINESS WIRE)--HealthCap VI L.P has pursuant to the subscription agreement entered into on 26 September 2013 between Nordic Nanovector AS (the “Company”), HealthCap VI L.P. and certain shareholders of the Company subscribed for 1,666,666 new shares at a subscription price of NOK 15 per share (MNOK 25 in total) (USD 3.9). The share capital increase related to the issuance of the new shares has now been registered with the Norwegian Register of Business Enterprises. The new share capital of the Company is NOK 5,297,608.2 divided into 26,488,041 shares, each with a nominal value of NOK 0.2.
About Nordic Nanovector AS
Nordic Nanovector AS is a privately held company established in 2009. The company is based in Norway and has offices and laboratories in Oslo. The company is developing novel innovative anticancer radioimmunotherapeutics to treat non-Hodgkin Lymphoma (NHL) and other hematological malignancies.
Betalutin™, is a pharmaceutical product candidate consisting of a radionuclide conjugated to a tumor seeking carrier/antibody, which can be used for irradiation of malignant metastasized tumors with minimal damage to nearby healthy normal tissue. This technology aims to prolong and improve the quality of life of people who suffer from non-Hodgkin Lymphoma (NHL).
This information was brought to you by Cision http://news.cision.com